Kim Jung A, Yoo Hye Jin
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Diabetes Metab J. 2025 Jul;49(4):525-541. doi: 10.4093/dmj.2025.0242. Epub 2025 Jul 1.
Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated considerable efficacy in the treatment of diabetes and obesity, it is essential to recognize that their use is associated with certain intrinsic risks that must not be disregarded. The incidence of adverse effects, particularly gastrointestinal complications, psychiatric disorders, and ocular problems, highlights the critical need for thorough patient assessment and continuous monitoring to ensure both the safety and effectiveness of treatment. Despite the possibility of adverse events, GLP-1 RAs continue to represent a crucial therapeutic modality for metabolic disturbances. This highlights the significance of ongoing research initiatives aimed at optimizing their safe utilization and refining current treatment protocols to improve patient outcomes. This review summarizes updated research findings regarding the adverse effects of GLP-1 RAs, their mechanisms of action, and guidelines for clinical application.
尽管胰高血糖素样肽-1受体激动剂（GLP-1 RAs）在治疗糖尿病和肥胖症方面已显示出相当大的疗效，但必须认识到，其使用与某些内在风险相关，这些风险不容忽视。不良反应的发生率，特别是胃肠道并发症、精神障碍和眼部问题，凸显了对患者进行全面评估和持续监测的迫切需要，以确保治疗的安全性和有效性。尽管存在不良事件的可能性，但GLP-1 RAs仍然是治疗代谢紊乱的关键治疗方式。这凸显了正在进行的研究计划的重要性，这些计划旨在优化其安全使用并完善当前治疗方案以改善患者预后。本综述总结了关于GLP-1 RAs不良反应、作用机制及临床应用指南的最新研究结果。
